Blurbs

H.C. Wainwright Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Springworks Therapeutics (SWTXResearch Report) today and set a price target of $103.00. The company’s shares closed yesterday at $27.15.

Burns covers the Healthcare sector, focusing on stocks such as Portage Biotech Inc, BioNTech SE, and Springworks Therapeutics. According to TipRanks, Burns has an average return of -21.0% and a 23.35% success rate on recommended stocks.

Springworks Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $103.00.

See the top stocks recommended by analysts >>

SWTX market cap is currently $1.69B and has a P/E ratio of -5.83.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SWTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm’s products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Read More on SWTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More